Pediatric Urology Research Enterprise, Department of Pediatric Urology, Children's Hospital Colorado, Aurora, CO, USA; Division of Urology, Department of Surgery, University of Colorado Denver Anschutz Medical Campus, Aurora, CO, USA.
Department of Pediatric Urology, Seattle Children's Hospital, Seattle, WA, USA.
J Pediatr Urol. 2024 Oct;20(5):911-920. doi: 10.1016/j.jpurol.2024.07.005. Epub 2024 Jul 16.
The opioid epidemic response led to increased use of postoperative, non-opioid analgesia. Some pediatric urologists do not routinely use non-steroidal anti-inflammatory drugs (NSAIDs) for fear of causing acute kidney injury (AKI). While previous studies have demonstrated the safety and efficacy of NSAIDs in children, safety after lower urinary tract reconstruction has not been well characterized.
ptUsing the Kidney Disease: Improving Global Outcomes (KDIGO) criteria for AKI (increase in creatinine ≥0.3 mg/dL or increase in creatinine ≥1.5x baseline or urine output <0.5 mL/kg/hr for 6 h), we hypothesized there would be a difference in the incidence of postoperative AKI between patients who did and did not receive NSAIDs following surgery.
Patients 2-18 years old who underwent lower urinary tract reconstruction (i.e., bladder augmentation and/or creation of a catheterizable channel) from 2009 to 2021 and had documented urine output were retrospectively reviewed. Chronic kidney disease (CKD) stage was calculated from creatinine and cystatin C within 6 months of surgery using the CKiD U25 equations. Patients who received NSAIDs were propensity matched on 11 characteristics with patients undergoing similar surgeries who did not receive NSAIDs. The primary outcome was incidence of AKI within 48 h of surgery.
The unmatched cohorts included 243 patients. Propensity matching identified 166 patients in the NSAID arm and 41 in the no NSAID arm. 26 patients with CKD stage 2-3 were included. There was no significant difference in the incidence of postoperative AKI based on any KDIGO criteria (17.1% no NSAID versus 16.3% NSAID, p = 0.87). Median postoperative opioids fell from 0.88 mg/kg in the no NSAID arm to 0.37 mg/kg morphine equivalents in the NSAID arm, although this was not statistically significant. Log-rank testing by Kaplan-Meier analysis demonstrated no difference in time to incidence of low urine output between the groups (p = 0.32). In the whole population not stratified by NSAID use, no differences were seen in AKI between those with and without CKD (16.7% with versus 17.9% without CKD).
There was no difference in the incidence of postoperative AKI among patients who did and did not receive NSAIDs after lower urinary tract reconstruction, excluding those with advanced CKD.
These results support that postoperative NSAIDs were an unlikely source of AKI. However, AKI remained a risk following these surgeries, regardless of NSAID use, likely owing to underlying disease, longer operations, and fluid shifts.
阿片类药物流行应对措施导致术后非阿片类镇痛剂的使用增加。一些小儿泌尿科医生由于担心会导致急性肾损伤 (AKI),因此不常规使用非甾体抗炎药 (NSAIDs)。尽管先前的研究已经证明了 NSAIDs 在儿童中的安全性和有效性,但在下尿路重建后的安全性尚未得到很好的描述。
使用肾脏疾病:改善全球结果 (KDIGO) AKI 标准(肌酐增加 ≥0.3mg/dL 或肌酐增加 ≥1.5x 基线或 6 小时内尿量 <0.5mL/kg/hr),我们假设接受和未接受 NSAIDs 的患者术后 AKI 的发生率会有所不同。
回顾性分析 2009 年至 2021 年间接受下尿路重建(即膀胱扩大和/或创建可导尿通道)且有记录尿量的 2-18 岁患者。使用 CKiD U25 方程,在手术前 6 个月内,根据肌酐和胱抑素 C 计算慢性肾脏病 (CKD) 分期。对接受 NSAIDs 的患者与接受类似手术但未接受 NSAIDs 的患者进行了 11 个特征的倾向性匹配。主要结局是手术 48 小时内 AKI 的发生率。
未匹配的队列包括 243 名患者。倾向性匹配确定了 NSAID 组 166 名患者和无 NSAID 组 41 名患者。包括 26 名 CKD 2-3 期患者。根据任何 KDIGO 标准,术后 AKI 的发生率均无显著差异(无 NSAID 组为 17.1%,NSAID 组为 16.3%,p=0.87)。尽管吗啡等效量的术后阿片类药物从无 NSAID 组的 0.88mg/kg 降至 NSAID 组的 0.37mg/kg,但这无统计学意义。通过 Kaplan-Meier 分析的对数秩检验表明,两组之间低尿量发生率的时间无差异(p=0.32)。在未按 NSAID 使用分层的整个人群中,CKD 患者与无 CKD 患者之间的 AKI 无差异(有 CKD 患者为 16.7%,无 CKD 患者为 17.9%)。
在下尿路重建后接受和未接受 NSAIDs 的患者中,AKI 的发生率无差异,排除 CKD 晚期患者。
这些结果支持术后 NSAIDs 不太可能是 AKI 的来源。然而,无论是否使用 NSAIDs,这些手术后 AKI 仍然是一个风险,可能是由于基础疾病、手术时间延长和液体转移所致。